These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 25644430)
1. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma. Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430 [TBL] [Abstract][Full Text] [Related]
2. Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma. Taulli R; Foglizzo V; Morena D; Coda DM; Ala U; Bersani F; Maestro N; Ponzetto C Oncogene; 2014 May; 33(18):2354-62. PubMed ID: 23728344 [TBL] [Abstract][Full Text] [Related]
3. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation. Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816 [TBL] [Abstract][Full Text] [Related]
4. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related]
5. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427 [TBL] [Abstract][Full Text] [Related]
6. SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function. Skrzypek K; Kusienicka A; Trzyna E; Szewczyk B; Ulman A; Konieczny P; Adamus T; Badyra B; Kortylewski M; Majka M Cell Death Dis; 2018 May; 9(6):643. PubMed ID: 29844345 [TBL] [Abstract][Full Text] [Related]
8. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. Belyea BC; Naini S; Bentley RC; Linardic CM Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088 [TBL] [Abstract][Full Text] [Related]
11. Cancer-Specific Energy Metabolism in Rhabdomyosarcoma Cells Is Regulated by MicroRNA. Sugito N; Taniguchi K; Kuranaga Y; Ohishi M; Soga T; Ito Y; Miyachi M; Kikuchi K; Hosoi H; Akao Y Nucleic Acid Ther; 2017 Dec; 27(6):365-377. PubMed ID: 28981396 [TBL] [Abstract][Full Text] [Related]
12. skNAC and Smyd1 in transcriptional control. Berkholz J; Orgeur M; Stricker S; Munz B Exp Cell Res; 2015 Aug; 336(2):182-91. PubMed ID: 26162853 [TBL] [Abstract][Full Text] [Related]
13. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271 [TBL] [Abstract][Full Text] [Related]
14. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma. Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas. Missiaglia E; Shepherd CJ; Aladowicz E; Olmos D; Selfe J; Pierron G; Delattre O; Walters Z; Shipley J Cancer Lett; 2017 Jan; 385():251-260. PubMed ID: 27984116 [TBL] [Abstract][Full Text] [Related]
16. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells. De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362 [TBL] [Abstract][Full Text] [Related]
17. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma. Saini M; Verma A; Mathew SJ Cell Death Dis; 2018 Feb; 9(2):237. PubMed ID: 29445192 [TBL] [Abstract][Full Text] [Related]
18. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice. van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124 [TBL] [Abstract][Full Text] [Related]
19. miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma. Diao Y; Guo X; Jiang L; Wang G; Zhang C; Wan J; Jin Y; Wu Z J Biol Chem; 2014 Jan; 289(1):529-39. PubMed ID: 24247238 [TBL] [Abstract][Full Text] [Related]
20. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma. Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]